From Yahoo Finance: 2025-04-25 12:49:00

AbbVie exceeded first-quarter sales and adjusted earnings per share expectations. The company raised its full-year EPS forecast by 10 cents. However, AbbVie noted potential impact from President Trump’s proposed tariffs on the industry. Sales of Skyrizi and Rinvoq saw significant growth, while Humira sales declined. AbbVie’s Q1 revenue includes $6.26 billion from these immunology drugs. President Trump plans to impose tariffs on the drug industry, which could affect AbbVie’s business. AbbVie shares rose nearly 3% following the positive earnings report.



Read more at Yahoo Finance: AbbVie Stock Rises on Stronger-Than-Expected Results, Profit Outlook Lift